Health Canada has issued a new Medical Devices Compliance Program Bulletin announcing further updates to the Medical Device Establishment Licence (MDEL) application form FRM-0292 and the associated guidance GUI-0016.
The bulletin, dated 30 October 2026, forms part of Health Canada’s broader work to modernize the MDEL licensing framework.
Health Canada had already updated the MDEL guidance and application form in June 2026. The latest bulletin introduces additional changes intended to simplify the application process and support industry’s transition to a new online submission system.
New Online Submission Process
One of the most significant changes is the move away from the existing PDF application form.
Health Canada states that the revised process is intended to replace the current Portable Document Format form with an online submission process.
The Agency has also:
reordered application sections;
removed redundancies;
updated instructions;
revised guidance wording to reflect the new process.
The objective is to streamline the user experience and make the MDEL application process more efficient.
Email Submission Will Be Discontinued
Under the revised system, MDEL applications will no longer be submitted by email.
Applicants will instead be required to access, complete and submit the application entirely online through the dedicated form links provided by Health Canada.
This represents an important procedural change for companies currently using the existing PDF-based workflow.
New Rules Take Effect on 1 December 2026
The amended regulations will come into force on 1 December 2026.
Health Canada notes that this is 180 days after the amendments were registered in the Canada Gazette, Part II on 4 June 2026.
The bulletin also corrects the coming-into-force date previously communicated in the 17 June 2026 Medical Devices Compliance Program Bulletin.
Mandatory Use of the New Form
Stakeholders will be required to use the new online application form once the Phase 2 regulatory amendments enter into force on 1 December 2026.
Until that date, Health Canada instructs applicants to continue using the existing PDF form.
Companies therefore need to manage the transition carefully depending on when their MDEL application is submitted.
Changes to Application Sections
Health Canada has also reorganised the structure of the application.
Sections 4 and 5 have been reordered:
Section 4 now relates to manufacturers and suppliers;
Section 5 now relates to sites.
Applicants should therefore review internal templates, procedures and supporting documentation to ensure information is mapped correctly to the revised structure.
Senior Official Signature Replaced
Another procedural change concerns the senior official declaration.
The previous senior official signature requirement has been replaced by an Acknowledgement.
The acknowledgement is completed by entering:
the individual’s position or title;
name;
date.
This change aligns the application with the new digital submission process.
Updated FRM-0292 and GUI-0016
The bulletin directs stakeholders to the revised:
Medical Device Establishment Licence Application: Instructions (FRM-0292);
Guidance on Medical Device Establishment Licensing (GUI-0016).
Applicants should ensure they are using the most current versions of both documents when preparing submissions under the new process.
Part of Phase 2 MDEL Modernisation
The new changes are in addition to amendments previously communicated under Phase 2 of Health Canada’s work to modernize medical device establishment licensing.
The update therefore forms part of a broader regulatory modernisation initiative rather than a standalone procedural change.
Impact on Medical Device Establishments
For organisations that require an MDEL, the update has direct operational implications.
Affected companies should review:
existing MDEL application SOPs;
responsibilities for preparing and submitting applications;
internal approval workflows;
senior official acknowledgement procedures;
manufacturer and supplier information;
site information;
application timing around the 1 December 2026 transition.
Teams that currently rely on email submission should also ensure access to and familiarity with the new online application process.
Transition Planning
The period before 1 December 2026 is particularly important.
Applications submitted before the regulatory amendments take effect should continue to use the existing PDF form, while applications from 1 December onward will need to follow the new online process.
Regulatory teams should therefore avoid mixing old and new procedures and clearly document which submission route applies to each application.
Impact on Importers and Distributors
MDEL requirements are particularly relevant to companies involved in activities such as importing or distributing medical devices in Canada where establishment licensing obligations apply.
These organisations should ensure that personnel responsible for licensing activities are aware of the new submission method and revised application structure.
Internal training may also be appropriate to reduce the risk of delays or incomplete applications during the transition.
Regulatory Operations Considerations
The shift to a fully online process may also affect regulatory operations teams.
Companies may need to update:
work instructions;
submission checklists;
document control systems;
approval processes;
training materials;
record-retention practices.
The change also reinforces the broader regulatory trend toward digital submission and electronic interaction with authorities.
Key Deadline
The main date for industry to monitor is:
1 December 2026
From this date, stakeholders will be required to use the revised online MDEL application process.
Until then, the existing PDF application form remains the appropriate route.
What Companies Should Do Now
Medical device establishments preparing for the change should consider:
reviewing the updated FRM-0292;
reviewing GUI-0016;
updating internal SOPs;
preparing teams for online submission;
checking whether applications should be filed before or after the 1 December transition;
reviewing the revised manufacturer, supplier and site sections;
updating senior official approval procedures.
Early preparation may help avoid disruption when the new application process becomes mandatory.
